Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: The role of streptogramins and other newer compounds

Diagnostic Microbiology and Infectious Disease

Volumn 33, Issue 2, 1999, Pages 101-112

  Jones, Ronald N ^a,b   Low, Donald E ^a,b   Pfaller, Michael A ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; BACITRACIN; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CLINAFLOXACIN; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GATIFLOXACIN; GENTAMICIN; GREPAFLOXACIN; KETOLIDE; LINEZOLID; METICILLIN; MOXIFLOXACIN; NITROFURANTOIN; OXACILLIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINUPRISTIN; STREPTOGRAMIN; STREPTOGRAMIN DERIVATIVE; STREPTOMYCIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CONFERENCE PAPER; ENTEROCOCCUS; EPIDEMIOLOGY; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MICROBIAL; ENTEROCOCCUS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIAE; VIRGINIAMYCIN;

EID: 0033044320     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(98)00108-4     Document Type: Conference Paper

References (65)

1. Anonymous. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. JAMA. 278:1997;891-892.
2. Archer G.L. Staphylococcus aureus: A well-armed pathogen . Clin Infect Dis. 26:1998;1179-1181.
3. Arthur M., Reynolds P.E., Depardieu F., Evers S., Dutka-Malen S., Quintiliani R. Jr, Courvalin P. Mechanisms of glycopeptide resistance in enterococci. J Infect Dis. 32:1996;11-16.
4. Barry A.L., Fuchs P.C., Brown S.D. Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests. J Antimicrob Chemother. 39:(suppl A):1997;87-92.
5. Biavasco F., Giovanetti E., Miele A., Vignaroli C., Facinelli B., Varaldo P.E. In vitro conjugative transfer of Van A vancomycin resistance between enterococci and Listeriae of different species. Eur J Clin Microbiol Infect Dis. 15:1996;50-59.
6. Boyce J.M., Opal S.M., Chow J.W., Zervos M.J., Potter-Bynoe G., Sherman C.B., Romulo R.I., Fortna S., Medeiros A.A. Outbreak of multi drug-resistant Enterococcus faecium with transferable van B class vancomycin-resistant enterococci. J Clin Microbiol. 32:1994;1148-1153.
7. Boyle J.F., Saumakis S.A., Rendo A., Herrington J.A., Gianarkis D.G., Thurberg B.E., Painter B.G. Epidemiologic analysis and genotypic characteristic of a nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol. 31:1993;1280-1285.
8. Breiman R.F., Butler J.C., Tenover F.C., Elliot J.A., Facklam R.R. Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 271:1994;1831-1835.
9. Butler J.C., Hofmann J., Cetron M.S., Elliott J.A., Facklam R.R., Breiman R.F. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States An update from the Centers for Disease Control and Preventions' Pneumococcal Sentinel Surveillance System . J Infect Dis. 174:1996;986.
10. Caron F., Gold H.S., Wennersten C.B., Farris M.G., Moellering R.C. Jr, Eliopoulos G.M. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 41:1997;2749-2753.
11. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. MMWR Morb Mortal Wkly Rep. 42:1993;597-599.
12. Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol. 16:1995;105-112.
13. Chen Y.S., Marshall S.A., Winokur P.L., Coffman S.L., Wilke W.W., Murray P.R., Spiegel C.A., Pfaller M.A., Doern G.V., Jones R.N. Use of molecular and reference susceptibility testing methods in a multicenter evaluation of MicroScan dried overnight Gram-positive MIC panels for detection of vancomycin and high-level aminoglycoside resistance in enterococci. J Clin Microbiol. 36:1998;2996-3001.
14. Chow J.W., Donabedian S.M., Zervos M.J. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin Infect Dis. 24:1997;90-91.
15. Cormican M.G., Jones R.N. Emerging resistance to antimicrobial agents in Gram-positive bacteria. Drugs. 51:(suppl 1):1996;6-12.
16. de Lencastre H., de Jonge B.L., Matthews P.R., Tomasz A. Molecular aspects of methicillin resistance in Staphylococcus aureus. J Antimicrob Chemother. 33:1994;7-24.
17. Doern G.V., Brueggeman A., Holley H.P. Jr, Rauch A.M. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995 Results of a 30-center national surveillance study . Antimicrob Agents Chemother. 40:1996;1208-1213.
18. Doern G.V., Ferraro M.J., Brueggemann A.B., Ruoff K.L. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother. 40:1996;891-894.
19. Edmond M.B., Ober J.F., Weinbaum D.L., Wenzel R.P. Vancomycin-resistant enterococcal bacteremia Natural history and attributable mortality . Clin Infect Dis. 23:1996;1234-1239.
20. Eliopoulos G.M. Vancomycin-resistant enterococci. Infect Dis Clin N Am. 11:1997;851-863.
21. Ena J., Dick R.W., Jones R., Wenzel R.P. The epidemiology of intravenous vancomycin usage in a university hospital. JAMA. 269:1993;598-602.
22. Feldman R.J., Paul S.M., Silber J.L., Cody R.P., Noveck H., Weinstein M.P. An analysis of treatment of patients with vancomycin-resistant enterococcal bacteremia. Infect Dis Clin Prac. 5:1996;440-445.
23. Garner J.S. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol. 17:1996;53-80.
24. Garrett D.O., Jochimsen E., Murfitt K. The impending apocalypse The emergence of vancomycin resistance in Staphylococcus spp. (abst S1) . Infect Control Hosp Epidemiol. 18:1997;32.
25. Gaynes R. The impact of antimicrobial use on the emergence of antimicrobial-resistant bacteria in hospitals. Infect Dis Clin N Am. 11:1997;757-765.
26. Gooding B.B., Jones R.N. In vitro antimicrobial activity of CP-99,219, a novel azabicyclonaphthyridone. Antimicrob Agents Chemother. 37:1993;349-353.
27. Handwerger S., Skoble J., Discotto L.F., Pucci M.J. Heterogeneity of the van A gene cluster in clinical isolates of enterococci from the northeastern United States. Antimicrob Agents Chemother. 39:1995;362-368.
28. Hansman D., Bullen M.M. A resistant pneumococcus. Lancet. 2:1967;264-265.
29. Herwaldt L.A., Geiss M., Kao C., Pfaller M.A. The positive predictive value of isolating coagulase-negative staphylococci from blood cultures. Clin Infect Dis. 22:1996;14-20.
30. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 40:1997;135-136.
31. Jacobs M.R., Koornhof H.J., Robins-Browne R.M. Emergence of multiply resistant pneumococci. N Engl J Med. 199:1978;735-740.
32. Jarvis W.R. Epidemiology, appropriateness, and cost of vancomycin use. Clin Infect Dis. 26:1998;1200-1203.
33. Jones R.N. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Am J Med. 100:(suppl 6A):1996;3S-12S.
34. Jones R.N., Barrett M.S. Antimicrobial activity of SCH 27899, oligosaccharide member of the everninomycin class with a wide Gram-positive spectrum. J Clin Microbiol Infect. 1:1995;35-43.
35. Jones R.N., Ballow C.H., Schentag J.J., Johnson D.M., Dienhart J.A. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis. Diagn Microbiol Infect Dis. 31:1998;313-325.
36. Jones R.N., Ballow C.H., Biedenbach D.J., Deinhart J.A., Schentag J.J. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid®) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis. 30:1998;437-451.
37. Jones R.N., Barry A.L., Gardiner R.V., Packer R.R. The prevalence of staphylococcal resistance to penicillinase-resistant penicillins A retrospective and prospective national surveillance trial of isolates from 40 medical centers . Diagn Microbiol Infect Dis. 12:1989;385-394.
38. Jones R.N., Johnson D.M., Erwin M.E. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother. 40:1996;720-726.
39. Jones R.N., Kehrberg E.N., Erwin M.E., Anderson S.C. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the treat of emerging resistances Real or perceived? Diagn Microbiol Infect Dis. 19:1994;203-215.
40. Jones R.N., Marshall S.A., Pfaller M.A., Wilke W.W., Hollis R.J., Erwin M.E., Edmond M.B., Wenzel R.P. Nosocomial enterococcal blood stream infections in the SCOPE Program Antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy . Diagn Microbiol Infect Dis. 29:1997;95-102.
41. Jones RN, Pfaller MA, Doern GV, Verhoef J, Jones ME, Sader HS, SENTRY Study Group (1997) Initial report of longitudinal, international antimicrobial surveillance study (SENTRY): Alarming resistance rates in monitored sites (68 medical centers) in the USA, Canada, South America, and Europe (abstr E-109). Proceedings of the 37th ICAAC. Washington, DC: American Society for Microbiology.
42. Jones R.N., Sader H.S., Erwin M.E., Anderson S.C. Emerging resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Diagn Microbiol Infect Dis. 21:1995;85-93.
43. Klugman K., Goldstein F., Kohno S., Baquero F. The role of fourth-generation cephalosporins in the treatment of infections caused by penicillin-resistant streptococci. Clin Microbiol Infect. 3:(suppl 1):1997;S48-S53.
44. Kotilainen P., Nikoskelainen J., Huovinen P. Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. J Infect Dis. 161:1990;41-44.
45. Linden P.K., Pasculle A.W., Manez A.R., Kramer D.J., Fung J.J., Pinna .Ad, Kusne S. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis. 22:1996;663-670.
46. Maranan M.C., Moreira B., Boyle-Vavra S., Daum R.S. Antimicrobial resistance in staphylococci. Infect Dis Clin N Am. 11:1997;813-839.
47. Marshall S.A., Wilke W.W., Pfaller M.A., Jones M.A. Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections Frequency of occurrence, antimicrobial susceptibility, and molecular (mec A) characterization of oxacillin resistance in the SCOPE Program . Diagn Microbiol Infect Dis. 30:1998;205-214.
48. Moellering R.C. Jr. Introduction Problems with antimicrobial resistance in Gram-positive cocci . Clin Infect Dis. 26:1998;1177-1178.
49. Moellering R.C. Jr. Vancomycin-resistant enterococci. Clin Infect Dis. 26:1998;1196-1199.
50. Moellering RC Jr, Cerwinka SI (1997) Early clinical results with quinupristin/dalfopristin for the therapy of bacteremia due to resistant Gram-positive bacteria. In: New macrolides, azalides, streptogramins in clinical practice (ICMAS III). Eds, Zinner S, Young L, Acar J, Neu H. New York: M. Dekker, pp. 173-176.
51. Performance standards for antimicrobial disk susceptibility tests-5th ed. Approved standard. NCCLS Document M2-A5. 1997;NCCLS, Wayne, PA.
52. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically-3rd ed. Approved standard NCCLS Document M7-A3. 1997;NCCLS, Wayne, PA.
53. Performance standard for antimicrobial susceptibility testing. Document M100-S8. 1998;NCCLS, Wayne, PA.
54. Noble W.C., Virani Z., Cree R.G.A. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett. 93:1992;195-198.
55. Panililio A., Culver D.H., Gaynes R.P., Banerjee S., Henderson T.S., Tolson J.S., Martone W.J. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol. 13:1992;582-586.
56. Pfaller M.A., Jones R.N., Doern B.F., Kugler K. Bacterial pathogens isolated from patients with blood stream infection Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997) . Antimicrob Agents Chemother. 42:1998;1762-1770.
57. Pyart C., Pierre C., Quesne G., Pron B., Berche P., Trieu-Cuot P. Emergence of vancomycin resistance in the genus Streptococcus Characterization of a van B transferable determinant in Streptococcus bovis . Antimicrob Agent Chemother. 41:1997;24-29.
58. Rosenberg J., Tenover F.C., Wong J., Jarvis W., Vugia D.J. Are clinical laboratories in California accurately reporting vancomycin-resistant enterococci? J Clin Microbiol. 35:1997;2526-2530.
59. Sanyal D., Johnson A.P., George R.C., Cookson B.D., Williams A.J. Peritonitis due to vancomycin-resistant Staphylococcus epidermidis. Lancet. 337:1991;54.
60. Schmidt L.H., Sesler C.L. Development of resistance to penicillin by pneumococci. Proc Soc Exp Biol Med. 52:1943;353-357.
61. Schwalbe R.S., Stapleton J.T., Gilligan P.H. Emergence of vancomycin resistant coagulase-negative staphylococci. N Engl J Med. 316:1987;927-931.
62. Seppala H., Nissinen A., Jarvinen J., Huovinen S., Henriksson T., Herva E., Holm S.E., Jahkola M., Katila M.L., Klaukka T. Resistance to erythromycin in group A streptococci. N Engl J Med. 326:1992;292-297.
63. Trucksis M., Hooper D.C., Wolfson J.S. Emerging resistance to fluoroquinolones in staphylococci An alert . Ann Intern Med. 114:1991;424-426.
64. Weinstein M.P., Towns M.L., Quartey S.M., Mirrett S., Reimer L.G., Parmigiani G., Reller L.B. The clinical significance of positive blood cultures in the 1990s A prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults . Clin Infect Dis. 24:1997;584-602.
65. Wenzel R.P., Edmond M.B. Vancomycin-resistant Staphylococcus aureus: Infection control considerations. Clin Infect Dis. 27:1998;245-251.